The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Liposomal irinotecan + fluorouracil/leucovorin after progression in mPDAC
Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Republic of Korea, outlines the results of an analysis evaluating the clinical benefit of liposomal irinotecan plus fluorouracil/leucovorin after conventional irinotecan-containing chemotherapy for patients with metastatic pancreatic adenocarcinoma (mPDAC). In this patient population, the addition of liposomal irinotecan plus fluorouracil/leucovorin showed only modest efficacy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
